Intellia Therapeutics (NTLA) Total Non-Current Liabilities (2015 - 2025)

Intellia Therapeutics (NTLA) has reported Total Non-Current Liabilities for 9 consecutive years, with $170.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 46.49% year-over-year to $170.7 million; the TTM figure through Dec 2025 stood at $170.7 million (down 46.49% YoY), while the FY2025 annual figure was $170.7 million, down 46.49% from the prior year.
• Total Non-Current Liabilities declined to $170.7 million in Q4 2025 per NTLA's latest filing, from $319.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.4 billion in Q1 2023 and bottomed at $170.7 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $781.8 million across 5 years, with a median of $1.1 billion in 2022.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 80.68% — and 2024, when it gained 27.21%.
• Intellia Therapeutics' Total Non-Current Liabilities stood at $1.3 billion in 2021, then sank by 79.88% to $260.5 million in 2022, then fell by 3.72% to $250.8 million in 2023, then grew by 27.21% to $319.1 million in 2024, then plunged by 46.49% to $170.7 million in 2025.
• Business Quant data shows NTLA's Total Non-Current Liabilities at $170.7 million in Q4 2025, $319.1 million in Q4 2024, and $250.8 million in Q4 2023.